Insmed’s Biogeneric Deemed Equal To Neupogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite regulatory murkiness, firm will forge ahead with new Phase III trial, CEO says.
You may also be interested in...
Insmed Chief Argues For Five-Year Biologics Exclusivity
Amgen was in the black on Neupogen/Neulasta three years after launch, CEO Allan contends.
Insmed Chief Argues For Five-Year Biologics Exclusivity
Amgen was in the black on Neupogen/Neulasta three years after launch, CEO Allan contends.
Rep. Thomas Teams Up With Insmed To Promote Follow-on Biologics
Former Rep. Bill Thomas continues his crusade for follow-ons and against Amgen in his new role as consultant to Richmond, Va.-based Insmed, which has big plans for follow-on biologics.